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Congestion, due in large part to hypervolemia, is the primary driver of heart failure (HF) admissions. Relief of congestion has been
traditionallyachieved throughtheuseofloopdiuretics,butthere isincreasingconcernthattheseagents,particularlyathighdoses,
may be deleterious in the inpatient setting. In addition, patients with HF and the cardiorenal syndrome (CRS) have diminished
response to loop diuretics, making these agents less eﬀective at relieving congestion. Ultraﬁltration, a mechanical volume removal
strategy, has demonstrated promise in achieving safe and eﬀective volume removal in patients with cardiorenal syndrome and
diuretic refractoriness. This paper outlines the rationale for ultraﬁltration in CRS and the available evidence regarding its use in
patients with HF. At present, the utility of ultraﬁltration is restricted to selected populations, but a greater understanding of how
this technology impacts HF and CRS may expand its use.
1.Introduction
Despite signiﬁcant advances in therapy and understanding
of the disease, heart failure (HF) continues to remain
a very morbid, mortal, and resource-consuming chronic
illness. The total estimated direct and indirect cost of HF
in the United States for 2010 is $39.2 billion [1]. Of
particular concern are patients admitted to the hospital with
congestion, as these patients are at greater risk of morbidity
and mortality than those with stable heart failure [2]. Mean
30-day mortality in these patients is slightly above 10%,
and the mean 30-day readmission rate is around 30% [3].
Dyspnea, a symptom of congestion and volume overload, is
present in almost 90% of patients admitted to the hospital
with heart failure [4]. Therapy aimed at relieving congestion
and volume overload is therefore essential; prevention of
recurrent volume accumulation is critical to disease stabi-
lization. For over 50 years, the use of loop diuretics has
been the main way to achieve ﬂuid loss and decongestion.
As heart failure progresses, patients may develop a declining
renal function and a diuretic unresponsiveness, a condition
termed the cardiorenal syndrome (CRS), which may make
volume removal with diuretics diﬃcult. It is in this setting
thatalternativemeansofﬂuidremovalrequireconsideration.
This paper focuses on a mechanical method of ﬂuid removal
known as ultraﬁltration.
2.Loop Diuretics:The Mainstayof
Therapy for Volume Overload
As mentioned above, the predominant reason that HF
patients present to the hospital is due to symptoms of
congestion. These symptoms are usually associated with
venous congestion and volume overload. In addition, signs
of elevated venous congestion, namely a third heart sound
and jugular venous distention, portend a poor prognosis in
HF patients [5]. It is critically important, therefore,to reduce
venous congestion prior to the development of symptoms
and also to quickly relieve symptoms of congestion once
present. This has been accomplished almost exclusively via
the use of loop diuretics since about 1965. Loop diuretics
block the sodium-potassium-chloride transporter in the
ascending limb of the Loop of Henle. In order to act, they
must be secreted into the tubular lumen. The pharma-
cokinetics and pharmacodynamics of these agents can vary
considerably from patient to patient, and therefore these
agents must be titrated to eﬀective doses while minimizing
toxicity [6]. With over 40 years of clinical experience in2 International Journal of Nephrology
using these agents, loop diuretics have been given a level
A recommendation to restore and maintain normal volume
status in HF patients in the Heart Failure Society of America
practice guidelines [7], despite the availability of large-scale
randomized trials which would be required to garner such a
recommendation for a novel agent. There are problems with
loop diuretics that have caused many to question their use,
especially in the setting of decompensation.
3.DiureticResistance
Diuretic resistance, simply deﬁned, is the progressive lack of
eﬃcacy of a given dose of diuretic to achieve an adequate
urinary response. This necessitates the use of higher doses
and combinations of loop and nonloop diuretics to achieve
sodiumandﬂuidloss,oftenattheexpenseofworseningrenal
function. Many factors contribute to the development of
diureticresistance.Worseningrenalinsuﬃciencyleadstoless
secretionofdiureticintothetubularﬂuid,requiringagreater
overall dose of diuretic in order for an eﬀective amount of
diuretic to reach its site of action [6]. Increased activation
of the renin-angiotensin-aldosterone system, induced by
diuretic use, results in increased sodium and water reabsorp-
tion through a variety of mechanisms. Hypertrophy of distal
tubule epithelial cells results in greater sodium absorption
distaltotheLoopofHenle,thesiteofactionofloopdiuretics
[8]. In patients with decompensated heart failure, venous
pressure is also elevated, leading to decreased absorption
of oral agents and decreased renal blood ﬂow and renal
sodium excretion [9]. Diuretic resistance is often found to
coexist with renal insuﬃciency in patients with HF and,
when present, deﬁnes the cardiorenal syndrome.
4.LoopDiureticsMayBeHarmful
In addition to having diminished eﬃcacy in patients with
CRS, loop diuretics themselves, particularly when adminis-
tered in high doses in an inpatient setting, may be harmful.
Retrospective analyses of large multicenter trials of patients
with HF have shown a consistent trend that nonpotassium
sparing diuretics (NPSDs), of which loop diuretics are the
primaryagentsused,areassociatedwithworsenedoutcomes.
An analysis of the Studies of Left Ventricular Dysfunction
(SOLVD), a seminal randomized trial demonstrating the
beneﬁt of ACE inhibition in the progression of HF, demon-
strated a higher all-cause and cardiovascular mortality
in subjects on NPSDs versus those who were not [10].
These diﬀerences were not signiﬁcant after multivariable
adjustment, but a higher risk of arrhythmic death in patients
onNPSDspersisted.AnanalysisoftheDigitalisInvestigation
Group (DIG) trial, conducted to evaluate the inﬂuence of
digoxin in mild-to-moderate chronic HF, also showed an
increased risk of death, cardiovascular death, progressive
HF death, sudden cardiac death, and HF hospitalizations
in subjects on NPSDs [11, 12]. A subsequent study of over
1300 patients with advanced heart failure at a single center
demonstrated a linear decrease in survival with increasing
outpatient dose of loop diuretic [13]. This association
persisted in multivariable analysis.
The Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Eﬀectiveness (ESCAPE)
trial, conducted to evaluate the use of pulmonary artery
catheter in subjects admitted to the hospital with advanced
heart failure, found a similar dose-response relationship
between inpatient loop diuretic dose and adjusted 6-month
mortality [14]. Using the Acute Decompensated Heart Fail-
ure(ADHERE)nationalregistry,alargenationwidedatabase
of patients admitted to the hospital with heart failure, inves-
tigators were able to demonstrate that subjects receiving an
inpatient intravenous dose of less than 160mg of furosemide
equivalents had lower in-hospital mortality, fewer episodes
of worsening renal function, and shorter length of stay than
subjects treated with >160mg of furosemide equivalents
per day, after propensity adjustment [15]. These association
studies do not prove causation, and it is certainly possible
that the need for a loop diuretic or a higher dose of loop
diuretic is simply reﬂective of a greater HF disease severity
and not an increased risk attributable to the loop diuretic
itself. Small clinical trials have demonstrated short-term
adverse clinical outcomes with higher doses of intravenous
loop diuretics [16, 17]. One mechanism through which
loop diuretics may exert a negative prognostic inﬂuence is
hypokalemia, which may lead to ventricular arrhythmias.
Activation of the renin-angiotensin-alsoterone system and
sympathetic nervous system [18–20], known to inﬂuence
HF progression, has been postulated as another potential
mechanism. In a porcine model of pacing-induced HF,
furosemide administration shortened time to left ventricular
dysfunction, and serum aldosterone levels were signiﬁcantly
higher in the furosemide-treated animals [21].
The recently presented NIH-sponsored Diuretic Opti-
mization Strategies Evaluation (DOSE) study was the ﬁrst
randomized trial of diuretic therapy in heart failure. It
randomized patients admitted with decompensated HF and
high outpatient diuretic dose (between 80mg and 240mg of
furosemide daily) to high doses (2.5 times oral dose) and
low doses (equivalent oral dose) of furosemide as well as
continuous infusion versus intermittent therapy in a 2 × 2
factorial design. The change in creatinine from baseline to 72
hours was low and not diﬀerent among groups. In the high
dose group, there was a higher rate of creatinine elevation
>3mg/dL,butthisdidnottranslateintoanydiﬀerencein60-
day outcomes. Sixty day rate of death, rehospitalization, or
EDvisitwasnotdiﬀerentamonggroupsandapproached45–
50%.Thestudydoesprovidesomeshort-termdataregarding
the safety of intravenous loop diuretics in the inpatient
setting. Lower dose diuretic therapy may be preferred as an
initial approach, provided that the dose is escalated if there is
suboptimal response at 48 hours.
5.What Is Ultraﬁltration andHow Does It
Differ from Hemodialysis?
For nonnephrologists, it is useful to brieﬂy review the
underlying concepts of ultraﬁltration (UF). UF involves a
convective transfer of water and solutes (Figure 1). Plasma
water is forced across a semipermeable membrane that
allows movement of water and solutes (small molecules lessInternational Journal of Nephrology 3
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Figure 1: Dialytic techniques used in decompensated heart failure.
Slow continuous ultraﬁltration (SCUF) uses a hydrostatic pressure
diﬀerence (ΔP) between the blood and nonblood sides of the
membrane (dotted line within the dialyzer) to remove water and
solutes from the plasma by ultraﬁltration. Sustained low-eﬃciency
dialysis (SLED) has the additional feature of dialysis ﬂuid passed
through the nonblood compartment in a countercurrent direction
to the blood ﬂow. Fluid removed from the blood must be replaced
by transfer from the interstitial compartment. Failure of this ﬂuid
recovery will result in hemodynamic instability.
than 20kDa) across the ﬁlter based on the transmembrane
pressure diﬀerence (ΔP) between the blood and ﬁltrate sides
of the ﬁlter. Solute particles that are smaller than the ﬁlter
pores can be “dragged” across into the ultraﬁltrate with
plasma water and are in the same concentration in the
ultraﬁltrate as they are in the preﬁlter plasma; thus the
ultraﬁltrate, or volume removed, is isotonic to plasma. The
magnitude of water and solute clearance is proportional to
the amount of ultraﬁltrate formed and can be manipulated
by changing the ΔP (i.e., by increasing the blood ﬂow or
by applying suction to the ﬁltrate side). In slow continuous
UF, the approach favored in HF patients, the amount of
ultraﬁltrate created is small (generally 2–4mL/minute) and
does not require replacement ﬂuid infusion. The higher the
rate of ultraﬁltrate formed, the greater the chance of causing
hemoconcentrationandintravascularvolumedepletion.The
goal is to remove volume at the same rate it can be recovered
from the extravascular space. UF is generally used when
loss of plasma water (and not solute clearance) is the main
goal of therapy [22]. As most patients with HF have no
need for solute exchange, this is the preferred and most
studied method for mechanical volume removal in HF
patients. The development of lower ﬂow UF systems not
requiring conventional dialysis catheters but rather large
bore IV catheters has also led to potential implementation by
nonrenal physicians and staﬀ, also making this technology
more broadly applied.
Conversely, the primary purpose of hemodialysis (HD)
is solute exchange, not volume removal. In HD, solute
transport occurs by passive diﬀusion and generally favors
clearance of small molecules less than ∼300Da in size. The
patient’s blood and dialysate are separated by a semiper-
meable membrane with relatively small pores. Electrolytes
and other solute particles small enough to pass through
membraneporesdiﬀusefreelydowntheirconcentrationgra-
dients,leadingtheoreticallytoequalconcentrationsoneither
side of the membrane. A process known as hemodiaﬁltration
combinesHDandUFbyrunningdialysatecountercurrentto
blood ﬂow and applying a pressure gradient across the mem-
brane, yielding both diﬀusive and convective clearance. The
large amount of ultraﬁltrate created necessitates replacement
ﬂuid infusion.
6. ClinicalTrialsof UF inPatientswith HF
Marenzi et al. studied the eﬀects of UF in 24 patients with
refractory CHF admitted to the cardiac intensive care unit
for treatment of heart failure [23]. All had signs of volume
overload.AllpatientsweretreatedwithUFviaaconventional
CRRT machine; access was via a double lumen y-shaped
catheter in a femoral vein. UF resulted in an average of 4.9L
of ﬂuid removal over a 9-hour period. Symptoms improved,
and the response to subsequent diuretic therapy was
enhanced, with a reduction in mean dose of diuretic follow-
ing UF therapy. All patients had continuous hemodynamic
data available via a Swann-Ganz catheter as well as invasive
arterial pressure via an arterial line. No changes in heart
rate, mean blood pressure, or systemic vascular resistance
were observed, while mean right atrial pressure, pulmonary
capillary wedge pressure, and mean pulmonary artery pres-
sure were reduced. Intravascular volume, as estimated by
hematocrit values, remained stable throughout the entire
time of treatment despite the large amount of ﬂuid removed
overall.Afallinﬁllingpressureswithstablehematocitduring
UFindicatedthataproportionalvolumeofﬂuidwasreﬁlling
the vasculature from the congested interstitium. This and
other uncontrolled studies of UF in HF [24–26] showed that
UF could be performed safely and could result in signiﬁcant
volume removal and symptom relief. These studies were
performed using conventional renal dialysis equipment, but
they led to the development of proprietary systems that were
less cumbersome, lacked the need for central venous access,
and required less specialized expertise to operate. In order
to gain FDA approval for such equipment, randomized trials
were required, which led to more robust data regarding the
safety and eﬃcacy of UF in patients with HF.
Costanzo et al. examined the utility of UF at a single
centerin20patientsadmittedwithHF,volumeoverload,and
renal insuﬃciency or diuretic resistance, deﬁned as serum
creatinine ≥1.5mg/dL or furosemide >80mg/day. Patients
must not have had more than one diuretic dose prior to
enrollment and must have been enrolled within 12 hours of
admission. Major exlusion criteria were hematocrit >40%,
systolic BP <85mmHg, IV vasoactive therapy. Improvement
in volume overload after ultraﬁltration persisted at 30 and 90
days post discharge and no changes in renal function, elec-
trolytes, or systolic BP were observed at hospital discharge,
30days,or90dayspostdischarge.Symptomscoresimproved
byhospitaldischargeandtheseimprovementsweresustained4 International Journal of Nephrology
at 30 and 90 days. Notably, in the 3 months preceding
ultraﬁltration, 10 hospitalizations occurred in 9 patients.
After ultraﬁltration, one patient was admitted within 30 days
and two more were admitted between 30 and 90 days for
unrelated causes (not complications of UF and not CHF);
medications did not change signiﬁcantly for the 20 patients
[27]. This study showed promising durability of the ﬂuid
removal by UF in addition to the short-term gains seen in
prior studies but was limited by the lack of a control group.
The Relief for Acutely ﬂuid-overloaded Patients with
decompensated CHF (RAPID-CHF) trial was the ﬁrst clin-
ical trial to test the use of a less invasive UF device (System
100, CHF Solutions, Brooklyn Park, MN) that used a single
16-g intravenous catheter in the antecubital fossa rather
than central venous access like most conventional devices
capable of UF. This study was unblinded. A total of 40
patients were enrolled at 6 sites and randomized 1:1 to
usual care or UF plus usual care. Inclusion criteria were
inpatient admission with primary diagnosis of CHF, 2+
lower extremity edema, and one other sign of increased
congestion. Major exclusion criteria included severe stenotic
valvular disease, acute coronary syndrome, systolic BP <
90mmHg at time of consent, hematocrit > 40%, poor
peripheralvenousaccess,andsevereconcomitantdisease.All
patients in the UF plus usual care group received a single
8-hour course of UF with ﬂuid removal rates determined
by the attending physician (up to 500cc/hr). Diuretics were
heldduringUF;thereafter,diureticswereadministeredatthe
discretion of the attending physician. Additional UF courses
were allowed at the discretion of the treating physician. The
primary endpoint was weight loss assessed at 24 hours after
consent was obtained. In this intention-to-treat analysis, 2
patients in the UF group did not receive UF: one due to
unsuccessful IV access and one due to inability to withdraw
blood from the catheter. There was greater volume removal
at 24 hours, but weight loss at 24 hours was not diﬀerent
between the two groups. Heart rate, systolic blood pressure,
a n de l e c t r o l y t e sw e r en o td i ﬀerent between the two groups
at 24 hours. Global dyspnea and CHF scores were improved
in the UF group. UF was well tolerated without clinically
signiﬁcant bleeding or hypotension. There was one catheter
siteinfectionrequiringa4-weekcourseofIVantibiotics[28].
The ultraﬁltration versus intravenous diuretics for
patients hospitalized for acute decompensated heart failure
(UNLOAD) trial [29] enrolled a total of 200 patients at 28
centers. Patients were eligible if admitted to the hospital and
enrolled within 24 hours with a primary diagnosis of heart
failure and with 2 signs of hypervolemia. Exclusions were
similar to RAPID-CHF, except that hematocrit had to be
less than 45% and serum creatinine had to be at or below
3.0mg/dL. Study participants were randomized to usual care
or usual care plus UF with the System 100 device (CHF
Solutions, Brooklyn Park, MN). Total extracorporeal blood
volume of this device is 33mL. All patients received 2g
sodium diet and 2000mL ﬂuid restriction. Subjects in the
usual care group received a minimum intravenous diuretic
of twice the before-hospitalization oral daily dose of diuretic.
Subjects in the UF group received UF at up to 500mL/hr
withdurationandratelefttodiscretionoftreatingphysician.
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Figure 2: UNLOAD trial, freedom from rehospitalization. Kaplan-
Meier estimate for freedom from rehospitalization for heart failure
within90daysofdischargeintheultraﬁltration(redline)andusual
care (blue line) groups.
Mean serum creatinine was 1.5mg/dL in both groups; mean
BNP was around 1300pg/mL; mean daily oral dose of loop
diuretic (furosemide equivalents) prior to admission was
120mg. Patients were followed for 90 days or until death.
Twentypatients(10%)diedby90days,9intheUFgroupand
11intheusualcaregoup;thestudywasnotpoweredtodetect
diﬀerences in mortality. The trial met one of its primary
eﬃcacy endpoints of improved weight loss at 48 hours, but
there was no diﬀerence in dyspnea score at 48 hours, the
other primary eﬃcacy endpoint. Dyspnea scores did not
correlate with other HF-related outcomes. Fewer patients in
the UF group required IV vasoactive therapies at 48 hours.
With regard to safety, signiﬁcant elevations in creatinine
were similar in both groups; no correlation was found
between ﬂuid removed and changes in serum creatinine in
either group. Hypotension during the 48hr period following
randomization was similarly low in both groups. Fewer
bleeding events occurred in the UF group than in the usual
care group. Hypokalemia (K < 3.5mEq/L) was less frequent
intheUFgroup.Withregardtosecondaryendpoints,lengths
of stay were similar despite greater ﬂuid loss in the UF group.
Oral furosemide doses at discharge were lower in the UF
group. Perhaps the most important observation in this study
was the decrease in HF hospitalizations, HF rehospitaliza-
tions, rehospitalization days per patient, and unscheduled
and emergency department visits for HF in the UF group
(Figure 2).Asubsequentanalysis[30]demonstratedthatthis
beneﬁt was consistent relative to those treated with bolus or
continuous infusion of intravenous diuretic.
Interestingly, there was a similar net ﬂuid loss between
subjects who received continuous infusion and those treated
with UF, yet hospitalization rate was still lower in the UF
group.
Liang et al. conducted a retrospective review of the expe-
rience at the Mayo Clinic using the System 100 device [31].
Patients in this small series had more advanced HF than in
RAPID CHF and UNLOAD. A protocol had been developed
prospectively in order to identify potential candidates for UF
therapy. Ultraﬁltrationwas attempted afterfailure of diuretic
and/or IV vasoactive therapies. The case series included 11
patients with volume overload, systolic BP > 90mmHg,International Journal of Nephrology 5
and diuretic refractoriness (as per the discretion of treating
physician). Three patients had constriction/restriction as the
etiology of heart failure, 2 had ischemic cardiomyopathy,
and none had nonischemic dilated cardiomypathy. Average
serum creatinine was 2.2mg/dL and average BUN was
69mg/dL. There were a total of 32 UF treatments that each
lasted 8 hours in duration. Of the total UF runs, 75%
removed more than 2500mL of ﬂuid, and 41% removed
>3500mL. There were no serious bleeding complications.
Notably, 5 out of 11 patients required dialysis on the same
or subsequent admission and 6-month mortality was 55%.
7.Costs
A recently published analysis using data derived from
the UNLOAD study indicated that UF was associated
with increased cost to society and the hospital versus IV
diuretics, but decreased cost to Medicare via a decrease in
hospitalizations for HF. The largest costs associated with
UF were that of single-use disposable ﬁlters required for
the proprietary UF system and hospital length of stay [32].
This analysis uses assumptions that tend to increase UF
costs above that which might be seen in the real world,
such as the use of multiple ﬁlters per patient and the use of
UF (with similar length of stay and ﬁlter use) in a patient
readmitted with HF who received UF during their index
admission. Some have argued that using a conventional HD
machine, which most hospitals already own, would reduce
capital expenditure. Filter costs are also signiﬁcantly lower
for these machines. Currently, the disadvantages of such an
approach, such as the need for central venous access and
trained personnel and the lack of eﬃcacy data supporting
the use of conventional dialysis equipment in this manner,
outweighthepotential savings[33,34]. Future maneuvers by
Medicare to incentivize hospitals to reduce readmission rates
for HF may create a more favorable ﬁnancial perspective for
this technology from a hospital standpoint.
8. FutureDirections
At this time, the reason for the increased eﬃcacy of UF
relative to diuretics is not clear. It does not appear to be
entirely due to the amount of volume removed. Some have
postulated that UF reduces levels of inﬂammatory cytokines,
but this has not been proven; UF should not be able to
clear such heavy molecules [35]. It is possible that relief of
congestion, however it is achieved, will allow greater eﬃcacy
of loop diuretics and that UF is simply a more direct way
to achieve this; the eﬃcacy of UF is not dependent on renal
function. Perhaps the removal of isotonic ﬂuid with UF
rather than hypotonic ﬂuid with loop diuretics (i.e., total
body sodium removal) is important [36]. Determining the
mechanisms by which UF beneﬁts HF patients, particularly
those with CRS, may allow us to further elucidate the
pathogenesis of CRS itself.
9. Conclusion
Congestion is the primary driver of admissions to the
hospitalduetoHF.Reliefofcongestionhasbeentraditionally
achieved through the use of loop diuretics, but there is
concern that these agents, particularly at high dose, may be
deleterious in the inpatient setting. In addition, patients with
advanced heart failure and the cardiorenal syndrome have
diminished response to loop diuretics, making these agents
less eﬀective at relieving congestion. Preliminary data using
UF, including a fairly large randomized trial, demonstrate
no major safety concerns, improved volume removal versus
diuretics alone, and decreased hospitalizations for HF at 90
days in selected patients. Major drawbacks are the increased
cost of this technology and the invasiveness of the approach.
Theoretical concerns, namely a predisposition to infectious
and bleeding complications, especially due to the need for
systemic heparinization during the procedure, have not been
borne out in clinical trials. At the present time based on
the available data, UF should be an inpatient therapeutic
modality reserved as a second-line approach in diuretic-
refractory patients (well above 80mg/day of oral furosemide
as outpatient and poor initial response to high-dose IV
diuretics inpatient) with adequate blood pressure.
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